Reuters logo
BRIEF-Neovacs and Biosense sign option agreement worth up to 65 million euros
February 21, 2017 / 6:39 AM / 10 months ago

BRIEF-Neovacs and Biosense sign option agreement worth up to 65 million euros

Feb 21 (Reuters) - Neovacs SA:

* And biosense sign option agreement worth up to 65 million euros ($68.80 million) plus royalties for Chinese development and commercial rights to Ifnalpha Kinoid for lupus and dermatomyositis

* Receives an upfront fee and is eligible for additional milestone payments and double digit sales royalties

* Receives option for development and commercial rights to Ifnalpha Kinoid for lupus and dermatomyositis in China and other selected territories Source text for Eikon: Further company coverage: ($1 = 0.9448 euros) (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below